| Outcome Measures: |
Primary: Primary Pharmacokinetic Endpoint - PK 1, Area under the human insulin and insulin lispro concentrations time curves, 0 - 10 hours|Primary Pharmacokinetic Endpoint - PK 2, Maximum observed concentration of human insulin and insulin lispro, 0 - 10 hours|Primary Pharmacodynamic Endpoint - PD 1, Area under the glucose infusion rate time curve, 0 - 10 hours|Primary Pharmacodynamic Endpoint - PD 2, Maximum observed glucose infusion rate, 0 - 10 hours | Secondary: Secondary Pharmacokinetic Endpoint - PK 1, Area under the insulin time curves at different intervals, 0 - 1 hour, 0 - 2 hours, 0 - 8 hours|Secondary Pharmacokinetic Endpoint - PK 2, Time to maximum insulin concentrations, 0 - 10 hours|Secondary Pharmacokinetic Endpoint - PK 3, Relative Efficiency of dose corrected ratio of AUC ins for INH and s.c. lispro, 0 - 10 hours|Secondary Pharmacokinetic Endpoint - PK 4, Onset of appearance (time from trial product administration until the serum insulin concentrations are \> LLOQ., 0 - 10 hours|Secondary Pharmacokinetic Endpoint - PK 5, Mean residence time of insulin, 0 - 10 hours|Secondary Pharmacodynamic Endpoint - PD 1, AUC for GIR at different time intervals, 0 - 1 hour, 0 - 2 hours, 0 - 8 hours|Secondary Pharmacodynamic Endpoint - PD2, Time to maximum glucose infusion rate, 0 - 10 hours|Secondary Pharmacodynamic Endpoint - PD3, Relative biopotency of dose corrected ratio of AUC GIR for INH and s.c. lispro, 0 - 10 hours
|
